Press release
Nonalcoholic Steatohepatitis Therapeutics Market Worth US$ 20.2 Billion by 2031 | CAGR: 13.6%: States TMR Report
Nonalcoholic Steatohepatitis Therapeutics
Nonalcoholic Steatohepatitis Therapeutics market is estimated to attain a valuation of US$ 20.2 Bn by the end of 2031, states a study by Transparency Market Research (TMR). Besides, the report notes that the market is prognosticated to expand at a CAGR of 13.6% during the forecast period, 2022-2031
๐๐๐ญ ๐ ๐๐๐ฆ๐ฉ๐ฅ๐ ๐๐จ๐ฉ๐ฒ ๐จ๐ ๐ญ๐ก๐ ๐๐๐ฌ๐๐๐ซ๐๐ก ๐๐๐ฉ๐จ๐ซ๐ญ -https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=7691
As there is no FDA-approved drug to treat nonalcoholic steatohepatitis, pharmaceutical companies and market stakeholders are expected to launch pipeline drugs to cure this silent liver disease. The global nonalcoholic steatohepatitis therapeutics market is driven by increase in global prevalence rate of diabetic and obesity, along with rise in awareness about the treatments and drugs available for the same.
Moreover, in order to boost credibility credentials, manufacturers are engaging in clinical trials of Elafibranor and various other drugs that help in reducing fat percentage in liver. Market stakeholders should focus on mergers & acquisitions and research collaborations with other companies to launch innovative products for the effective treatment of nonalcoholic steatohepatitis in the upcoming years.
๐๐ฎ๐ซ๐ ๐ ๐ข๐ง ๐๐ซ๐๐ฏ๐๐ฅ๐๐ง๐๐ ๐จ๐ ๐๐จ๐ง-๐๐ฅ๐๐จ๐ก๐จ๐ฅ๐ข๐ ๐๐ญ๐๐๐ญ๐จ๐ก๐๐ฉ๐๐ญ๐ข๐ญ๐ข๐ฌ ๐๐ข๐ฌ๐๐๐ฌ๐ ๐๐ฅ๐จ๐๐๐ฅ๐ฅ๐ฒ
Nonalcoholic steatohepatitis is a type of liver disease diagnosed in people who are non-alcoholic or consume alcohol in very low amount. Nonalcoholic steatohepatitis (NASH) is one of the commonly diagnosed liver diseases. The disease is also known as silent liver disease. Fat deposition in liver, along with inflammation is one of the significant conditions that occurs during the disease. The surge in the incidence rate of nonalcoholic steatohepatitis has increased the demand for therapeutics to treat the disease. Consequently, multiple drugs are being launched. These drugs aim to provide relief from the disease.
According to market analysts, the global nonalcoholic steatohepatitis therapeutics market is anticipated to witness double digit growth in the next few years. Increase in awareness among people about therapeutics is also a major factor boosting the growth of the market in various regions across the world. However, poor diagnostics and lack of proper diagnostic technique are projected to restrain the global market in the next few years.
๐๐ง๐ช๐ฎ๐ข๐ซ๐ ๐๐๐๐จ๐ซ๐ ๐ฉ๐ฎ๐ซ๐๐ก๐๐ฌ๐ - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=7691
๐๐๐ ๐ข๐จ๐ง๐๐ฅ ๐๐ฎ๐ญ๐ฅ๐จ๐จ๐ค ๐จ๐ ๐๐ฅ๐จ๐๐๐ฅ ๐๐จ๐ง๐๐ฅ๐๐จ๐ก๐จ๐ฅ๐ข๐ ๐๐ญ๐๐๐ญ๐จ๐ก๐๐ฉ๐๐ญ๐ข๐ญ๐ข๐ฌ ๐๐ก๐๐ซ๐๐ฉ๐๐ฎ๐ญ๐ข๐๐ฌ ๐๐๐ซ๐ค๐๐ญ
In terms of region, the global nonalcoholic steatohepatitis therapeutics market has been segmented into North America, Asia Pacific, Europe, Latin America, Middle East & Africa. North America dominated the global market, accounting for key share in 2021.
North America is significantly affected by NASH due to rise in population suffering from diabetes and obesity. Moreover, prevailing cases of high cholesterol and changes in lifestyle make North America an attractive market for future development and growth.
In Europe, countries such as Italy, Spain, Germany, the U.K., and France are the main areas with high prevalence of NASH. These countries are likely to be highly lucrative markets for nonalcoholic steatohepatitis therapeutics.
๐๐จ๐ฆ๐ฉ๐๐ญ๐ข๐ญ๐ข๐ฏ๐ ๐๐๐ง๐๐ฌ๐๐๐ฉ๐:
Intercept Pharmaceuticals, Inc., GENFIT SA, Zydus Cadila, Conatus Pharmaceuticals, and Tobira Therapeutics, Inc., AstraZeneca plc, Galmed Pharmaceuticals Ltd., Gilead Sciences, Inc., and Immuron Ltd.
๐๐๐ซ๐ค๐๐ญ ๐๐๐ ๐ฆ๐๐ง๐ญ๐๐ญ๐ข๐จ๐ง -
๐๐ซ๐ฎ๐ ๐๐ฒ๐ฉ๐
Obeticholic Acid (OCA)
Aramchol (Arachidyl Amido Cholanoic Acid)
Saroglitazar
Elafibranor
๐๐๐ฏ๐ ๐๐ง๐ฒ ๐๐ฎ๐๐ซ๐ฒ? ๐๐ฌ๐ค ๐๐จ ๐๐ง๐๐ฅ๐ฒ๐ฌ๐ญ: https://www.transparencymarketresearch.com/sample/sample.php?flag=ASK&rep_id=7691
๐๐๐ฒ ๐๐๐ฏ๐๐ฅ๐จ๐ฉ๐ฆ๐๐ง๐ญ๐ฌ ๐ข๐ง ๐๐ฅ๐จ๐๐๐ฅ ๐๐จ๐ง๐๐ฅ๐๐จ๐ก๐จ๐ฅ๐ข๐ ๐๐ญ๐๐๐ญ๐จ๐ก๐๐ฉ๐๐ญ๐ข๐ญ๐ข๐ฌ ๐๐ก๐๐ซ๐๐ฉ๐๐ฎ๐ญ๐ข๐๐ฌ ๐๐๐ซ๐ค๐๐ญ
In January 2019, Genfit took the first step toward making this test available, as it had signed a licensing agreement with LabCorp, the leading drug development and NASH clinical trial company, to expand the access to NIS4 in the global clinical research community
๐๐ก๐ข๐ฌ ๐๐๐ฉ๐จ๐ซ๐ญ ๐ฅ๐๐ญ๐ฌ ๐ฒ๐จ๐ฎ ๐ข๐๐๐ง๐ญ๐ข๐๐ฒ ๐ญ๐ก๐ ๐จ๐ฉ๐ฉ๐จ๐ซ๐ญ๐ฎ๐ง๐ข๐ญ๐ข๐๐ฌ ๐ข๐ง ๐๐จ๐ง๐๐ฅ๐๐จ๐ก๐จ๐ฅ๐ข๐ ๐๐ญ๐๐๐ญ๐จ๐ก๐๐ฉ๐๐ญ๐ข๐ญ๐ข๐ฌ ๐๐ก๐๐ซ๐๐ฉ๐๐ฎ๐ญ๐ข๐๐ฌ ๐๐๐ซ๐ค๐๐ญ ๐๐ฒ ๐ฆ๐๐๐ง๐ฌ ๐จ๐ ๐ ๐ซ๐๐ ๐ข๐จ๐ง:
North America (the United States, Canada, and Mexico)
Europe (Germany, UK, France, Italy, Russia, Turkey, etc.)
Asia-Pacific (China, Japan, Korea, India, Australia, and Southeast Asia (Indonesia, Thailand, Philippines, Malaysia, and Vietnam))
South America (Brazil etc.) The Middle East and Africa (North Africa and GCC Countries)
๐๐จ๐ซ๐ ๐๐ซ๐๐ง๐๐ข๐ง๐ ๐๐๐ฉ๐จ๐ซ๐ญ๐ฌ ๐๐ฒ ๐๐ซ๐๐ง๐ฌ๐ฉ๐๐ซ๐๐ง๐๐ฒ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฌ๐๐๐ซ๐๐ก -
๐๐ซ๐๐๐ข๐ฅ๐ฅ๐๐ ๐๐ฒ๐ซ๐ข๐ง๐ ๐๐ฌ ๐๐๐ซ๐ค๐๐ญ- https://www.prnewswire.com/news-releases/prefilled-syringes-market-to-exceed-value-of-us-35-7-bn-by-2031--tmr-study-301593032.html
๐๐ฎ๐๐๐ซ๐จ๐ฌ๐ ๐๐ฑ๐ญ๐ซ๐๐๐ญ ๐๐๐ซ๐ค๐๐ญ- https://www.prnewswire.com/news-releases/tuberose-extract-market-to-be-valued-at-us-413-5-mn-by-2031--tmr-report-301593208.html
๐๐๐จ๐ฎ๐ญ ๐๐ฌ ๐๐ซ๐๐ง๐ฌ๐ฉ๐๐ซ๐๐ง๐๐ฒ ๐๐๐ซ๐ค๐๐ญ ๐๐๐ฌ๐๐๐ซ๐๐ก
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. The firm scrutinizes factors shaping the dynamics of demand in various markets. The insights and perspectives on the markets evaluate opportunities in various segments. The opportunities in the segments based on source, application, demographics, sales channel, and end-use are analysed, which will determine growth in the markets over the next decade.
Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision-makers, made possible by experienced teams of Analysts, Researchers, and Consultants. The proprietary data sources and various tools & techniques we use always reflect the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in all of its business reports.
๐๐จ๐ง๐ญ๐๐๐ญ ๐๐ฌ
Nikhil Sawlani
Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Nonalcoholic Steatohepatitis Therapeutics Market Worth US$ 20.2 Billion by 2031 | CAGR: 13.6%: States TMR Report here
News-ID: 3346221 • Views: โฆ
More Releases from Transparency Market Research
Global SiC Ceramics Market Poised for Robust Growth, Projected to Reach USD 3.1 โฆ
The global silicon carbide (SiC) ceramics market continues to demonstrate strong growth potential, underpinned by accelerating demand from advanced industrial and electronic applications. Valued at US$ 1.8 Billion in 2024, the market is projected to reach US$ 3.1 Billion by 2035, expanding at a compound annual growth rate (CAGR) of 5.2% during the forecast period from 2025 to 2035. This steady expansion reflects the increasing importance of SiC ceramics asโฆ
Furfuryl Alcohol Market to Reach USD 1.34 Billion by 2035, Supported by Rising D โฆ
The global Furfuryl Alcohol Market was valued at US$ 624.3 million in 2024 and is projected to reach US$ 1,341.2 million by 2035, expanding at a compound annual growth rate (CAGR) of 7.2% from 2025 to 2035.
This growth is primarily driven by the rising demand for bio-based and sustainable chemicals, along with the steady expansion of the foundry and metal casting industry, particularly across emerging economies in Asia Pacific.
Gain aโฆ
Air-Entraining Agents Market Outlook 2035: Forecast to Reach US$ 2.48 Billion by โฆ
The global Air-Entraining Agents (AEAs) Market was valued at US$ 1.70 billion in 2024 and is projected to reach US$ 2.48 billion by 2035, expanding at a compound annual growth rate (CAGR) of 3.5% from 2025 to 2035. This steady growth trajectory reflects the essential role AEAs play in modern concrete formulations, particularly in infrastructure projects that demand long-term durability, freeze-thaw resistance, and improved workability.
Despite being a mature segment withinโฆ
A2P SMS Market Outlook 2035: Expanding from US$ 71.2 Bn in 2024 to US$ 117.0 Bn โฆ
The global Application-to-Person (A2P) SMS market is entering a phase of steady and resilient expansion, driven by the growing need for secure, reliable, and real-time communication between enterprises and consumers. Valued at US$ 71.2 Bn in 2024, the market is projected to reach US$ 117.0 Bn by 2035, expanding at a CAGR of 4.2% from 2025 to 2035. Despite the rise of internet-based messaging platforms, A2P SMS continues to maintainโฆ
More Releases for Nonalcoholic
Nonalcoholic Steatohepatitis (NASH) Market Massive Growth opportunity Ahead
Introduction
Nonalcoholic Steatohepatitis (NASH) is an advanced form of nonalcoholic fatty liver disease (NAFLD) characterized by fat accumulation in the liver along with inflammation and liver cell damage. If left untreated, NASH can progress to fibrosis, cirrhosis, liver failure, or hepatocellular carcinoma. Closely tied to the global obesity and diabetes epidemic, NASH has become a major healthcare burden, with millions affected worldwide and no widely approved curative therapy to date.
The NASHโฆ
Drinking Nonalcoholic Beer Market Size 2024 to 2031.
Market Overview and Report Coverage
Drinking nonalcoholic beer is a type of beverage that has gained popularity as a healthier alternative to traditional beer. It contains little to no alcohol, making it suitable for individuals looking to enjoy the taste of beer without the effects of alcohol. The market for drinking nonalcoholic beer is steadily growing, with a projected CAGR of 6.00% during the forecasted period.
The future outlook ofโฆ
Nonalcoholic Steatohepatitis Treatment Market Analysis
As per the research conducted by GME, the Global Nonalcoholic Steatohepatitis Treatment Market will grow with a CAGR value of 39.1% by 2026. Over the forecast era, the production of NASH biomarkers is expected to be aided by increasing demand for non-invasive diagnostic tools and increased patient awareness. The low use of invasive procedures for disease diagnosis is due to the high cost of liver biopsy, its invasiveness, and patients'โฆ
Nonalcoholic Steatohepatitis Therapeutics Market - Current status and future tre โฆ
The global nonalcoholic steatohepatitis therapeutics market is dominated by companies such as Intercept Pharmaceuticals Inc., GENFIT SA, Galmed Pharmaceuticals Ltd., Zydus Cadila, AstraZeneca plc., Gilead Sciences, Inc., and Immuron Ltd. Key companies are focusing on the introduction of new drugs and therapeutics to treat nonalcoholic steatohepatitis (NASH). As per the Natural Medical Journal, the occurrence of nonalcoholic fatty liver diseases is expected to increase in the U.S., which is likelyโฆ
Emerging Opportunities in Nonalcoholic Steatohepatitis Therapeutics Market
Global Nonalcoholic Steatohepatitis (NASH) Market: Snapshot
Nonalcoholic Steatohepatitis (NASH), a syndrome found in non-alcoholic patients, causes damage to liver that is histologically akin to alcoholic hepatitis. NASH results from fat in the liver, along with inflammation. Symptoms in NASH usually do not show, but it can be severe and lead to cirrhosis, which is permanent damage to the liver.
Those suffering from obesity, dyslipidemia, and glucose intolerance are most likelyโฆ
Global Nonalcoholic Steatohepatitis Therapeutics Market
Nonalcoholic Steatohepatitis (NASH), also called the โsilent disease,โ is a kind of fatty liver disease which typically affects people that are obese or diabetic. This disease is more prevalent in the younger generation and causes liver inflammation and/or damage owing to the accumulation of fat within the liver. The exact cause of this disease is still not clear; however, research activities are underway for finding effective treatments to cure thisโฆ
